NONS for COVID-19 Treatment [COVID-19]
Research type
Research Study
Full title
Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection
IRAS ID
287727
Contact name
Stephen Winchester
Contact email
Sponsor organisation
Ashford and St Peter's Hospitals NHS Foundation Trust
Eudract number
2020-004994-27
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
There is currently a worldwide pandemic caused by the respiratory virus SARS-CoV-2, or coronavirus for short. For a lot of people infected by COVID-19, they exhibit mild symptoms: dry cough, mild fever, tiredness, loss of smell. We are hoping Nitric Oxide Nasal Spray can act as suitable treatment for individuals with a mild infection.
There are currently no known drugs that can be administered as specific treatment against mild COVID-19 symptoms. NHS guidance is currently to quarantine for 10 days at home if you are experiencing COVID-19 symptoms.
The study is designed to look at the potential effects of nitric oxide (NO) in treating mild COVID-19 symptoms. Although initial data is promising, this study will help clarify the effects and potential of nitric oxide in COVID-19 treatment.
The NO (technically labelled drug) is delivered through a nasal spray over the course of 9 days. Current research indicates that nitric oxide is effective against viral infections and we are hoping to replicate its success against coronavirus by providing it as a treatment option to those with mild COVID-19 symptoms.
REC name
London - Brent Research Ethics Committee
REC reference
20/LO/1209
Date of REC Opinion
16 Nov 2020
REC opinion
Further Information Favourable Opinion